VSK Kerala
  • Home
  • വാര്‍ത്ത
    • കേരളം
    • ഭാരതം
    • ലോകം
    • കായികം
    • സംഘ വാര്‍ത്തകള്‍
    • സേവന വാര്‍ത്തകള്‍
    • ബുള്ളറ്റിൻ
  • English
    • Articles
    • Kerala
    • India
    • World
    • RSS in News
    • Seva News
  • ലേഖനങ്ങള്‍
  • സംസ്കൃതി
  • വീഡിയോ
  • RSS
    • RSS: Vision and Mission
    • Press Release
    • Resolutions
  • VSK
    • About Us
    • Activities
No Result
View All Result
VSK Kerala
  • Home
  • വാര്‍ത്ത
    • കേരളം
    • ഭാരതം
    • ലോകം
    • കായികം
    • സംഘ വാര്‍ത്തകള്‍
    • സേവന വാര്‍ത്തകള്‍
    • ബുള്ളറ്റിൻ
  • English
    • Articles
    • Kerala
    • India
    • World
    • RSS in News
    • Seva News
  • ലേഖനങ്ങള്‍
  • സംസ്കൃതി
  • വീഡിയോ
  • RSS
    • RSS: Vision and Mission
    • Press Release
    • Resolutions
  • VSK
    • About Us
    • Activities
No Result
View All Result
VSK Kerala
No Result
View All Result
Home English

AYUSH Ministry directs Strict Action against Gujarat firm for misleading claims for its product AAYUDH Advance

VSK Desk by VSK Desk
20 April, 2021
in English
ShareTweetSendTelegram

New Delhi. Acting upon a letter from the Ministry of Ayush, the Joint Commissioner (Ayurved) of Food & Drug Control Administration of Gujarat has issued show cause notice to a Rajkot based Ayurvedic drugs manufacturer which had made misleading claims for its product AAYUDH advance. The company has claimed that its said product is the ‘first clinically tested medicine for COVID-19 management and treatment’. The company has further claimed that its product is three times better than Remdisvir and that ‘AAYUDH Advance starts where vaccines stop’.

The drug policy section of the Ministry of Ayush had directed the Ayurvedic licensing authority of Gujarat to initiate strict action against the company that had made such misleading claims for its product AAYUDH advance.

In a letter issued on April 18th by Dr. S.R. Chinta, Deputy Advisor, Drug Policy section of the Ministry of Ayush, the Joint Commissioner of the Ayurvedic drugs’ Licensing Authority of Gujarat was asked to take strict and immediate action against M/s Shukla AsharImPexPvt. Ltd, Rajkot. The letter cited 5-6 reasons that invite strict action against the company.

The letter from Ayush Ministry pointed out grave misconduct on the part of the company regarding drug formulation related claims. Citing the Ayurvedic rule book, the letter said that the formulation was “violating Section 33 EEB which puts a particular drug in ‘Misbranded, Adulterated and Spurious Drug’ category.” The letter also cited Rule 158-B and said that its conditions were not fulfilled. This rule deals with licensing of 3(h) formulation and requires that “the ingredients should be part of Authoritative Books mentioned under First Schedule.”

It is noteworthy that the clinical study of the alleged product was referred to different committees, viz., ‘Interdisciplinary Ayush R&D Task Force on COVID-19’ and ‘Interdisciplinary Technical Review committee (ITRC)’. Both the committees had rejected the product as well as the clinical trial as it did not follow the principles of Ayurveda and study protocols.

It is worthwhile to mention that the company has claimed that this product is “..a liquid formulation comprising 21 different types of plant-based extracts. Ayurvedic Scriptures report these ingredients to be effective and safe to be used for human consumption.” To this claim the letter from the ministry clearly mentions that some of the ingredients in the formulation of the product in question are not mentioned in Ayurvedic classical text as prescribe in First Schedule of Drugs & Cosmetics Act 1940 hence it cannot be termed as Ayurvedic drugs under rule 3a & 3(h) (i) of Drugs and Cosmetics act 1940.

The Ministry had asked for the Action Taken Report by the Joint Commissioner (Ayurved) of the Gujarat Food & Drug Control Administration, acting on which the state authority has issued a 7 days’ show cause notice. It is worthwhile to note that the Ayush Ministry letter had also mentioned that the said drug ‘AAYUDH Advance’ was violating section 33EED for not having the therapeutic value as claimed by the manufacturer causing public grievance.

ShareTweetSendShareShare

Latest from this Category

Ivide Thaliridum Orottamottum Vaadi Kozhiju Veezhilla…

പഹൽഗാം ആക്രമണം നിന്ദ്യം : ആർഎസ്എസ്

Extremist Figures Featured in Protest Against Wakf Amendment

Devi Ahilya Revived Centers of Culture Destroyed by Invaders: Smriti Irani

Minorities in Bangladesh must be protected: Acharya Sivaswaroopananda Swamikal

Hunt Against Minorities in Bangladesh: A Dangerous Signal for India’s Hindu Community : J. Nandakumar

Load More

Discussion about this post

Latest News

Ivide Thaliridum Orottamottum Vaadi Kozhiju Veezhilla…

പഹൽഗാം ആക്രമണം നിന്ദ്യം : ആർഎസ്എസ്

Extremist Figures Featured in Protest Against Wakf Amendment

Devi Ahilya Revived Centers of Culture Destroyed by Invaders: Smriti Irani

Minorities in Bangladesh must be protected: Acharya Sivaswaroopananda Swamikal

Hunt Against Minorities in Bangladesh: A Dangerous Signal for India’s Hindu Community : J. Nandakumar

Delhi Hindu Sikh Global Forum protests in front of the Canadian Embassy against temple violence in Canada

Resistance is Compulsory; Munambam Stands in Solidarity with the Protest, Scrap the Waqf Act

Load More

Latest Malayalam News

സായുധ സേനയ്ക്കും കേന്ദ്ര സർക്കാരിനും അഭിനന്ദനം: ആർഎസ്എസ്

കൃഷ്ണശർമ്മ പുരസ്കാരം; അപേക്ഷ ക്ഷണിച്ചു

പാശ്ചാത്യ മാതൃകകള്‍ പരാജയം: ഡോ. മോഹന്‍ ഭാഗവത്

കസ്തൂരിരംഗന്‍ ദേശീയ ജീവിതത്തിലെ തിളക്കമുള്ള നക്ഷത്രം; ആര്‍എസ്എസ്

Load More

©Vishwa Samvada Kendram, Kerala.
Tech-enabled by Ananthapuri Technologies

No Result
View All Result
  • Home
  • വാര്‍ത്ത
    • കേരളം
    • ഭാരതം
    • ലോകം
    • കായികം
    • സംഘ വാര്‍ത്തകള്‍
    • സേവന വാര്‍ത്തകള്‍
    • ബുള്ളറ്റിൻ
  • English
    • Articles
    • Kerala
    • India
    • World
    • RSS in News
    • Seva News
  • ലേഖനങ്ങള്‍
  • സംസ്കൃതി
  • വീഡിയോ
  • RSS
    • RSS: Vision and Mission
    • Press Release
    • Resolutions
  • VSK
    • About Us
    • Activities

©Vishwa Samvada Kendram, Kerala.
Tech-enabled by Ananthapuri Technologies